Related Experiment Video

Updated: May 21, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Antirestenosis effect of butein in the neointima formation progression

Yen-Nien Chen1, Tur-Fu Huang, Chien-Hsin Chang

  • 1Department of Pharmacology, Tzu Chi University , Hualien, Taiwan.

Journal of Agricultural and Food Chemistry
|June 14, 2012
PubMed

Insights

Butein, a natural compound, effectively inhibits vascular smooth muscle cell proliferation and migration, key drivers of restenosis. This study shows butein

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Cell Biology

Background:

  • Restenosis, characterized by vascular smooth muscle cell (VSMC) hyperproliferation and migration, is a significant complication after angioplasty.
  • Platelet-derived growth factor (PDGF) is a critical mediator in the development of restenosis.
  • Butein, a known modulator of inflammatory pathways and tumor cell behavior, was investigated for its potential anti-restenotic effects.

Purpose of the Study:

  • To investigate the efficacy of butein in preventing restenosis by examining its effects on PDGF-induced VSMC proliferation and migration.
  • To elucidate the molecular mechanisms underlying butein's action on PDGF signaling pathways in VSMCs.

Main Methods:

  • In vitro studies utilized BrdU proliferation and two-dimensional migration scratch assays to assess VSMC proliferation and migration.
  • Western blotting was employed to analyze the phosphorylation status of key signaling molecules, including PDGF-receptor β, mitogen-activated protein kinases, phosphoinositide 3-kinase/Akt, and phospholipase Cγ/c-Src.
  • In vivo efficacy was evaluated in a rat carotid artery balloon injury model to assess neointima formation.

Main Results:

  • Butein significantly inhibited PDGF-induced proliferation and migration of VSMCs in vitro.
  • Butein suppressed the phosphorylation of PDGF-receptor β and downstream signaling pathways, including MAPK, PI3K/Akt, and PLCγ/c-Src, in a concentration-dependent manner.
  • Systemic administration of butein markedly attenuated neointima formation in balloon-injured rat carotid arteries.

Conclusions:

  • Butein effectively inhibits PDGF-induced VSMC proliferation and migration, suggesting a therapeutic potential for preventing restenosis.
  • The findings demonstrate that butein acts by repressing key signaling pathways involved in VSMC activation and proliferation.
  • This study provides the first evidence that systemic butein administration can reduce neointima formation following vascular injury, highlighting its potential as a novel anti-restenotic agent.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...